SubHero Banner

Tyvaso DPI (treprostinil) – New drug approval

May 24, 2022 - United Therapeutics announced the FDA approval of Tyvaso DPI (treprostinil), for the treatment of Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability and Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

Download PDF